Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Latest filing published 11 Feb 2026 for Adma Biologics, INC.. Read the official filing
Filing timeline
BuySaleYoung Kwon
Insider track record
Disclosed buys
2
Disclosed sells
1
T+90 hit rate
100%
T+90 mean return
+21.5%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Young Kwon: trading record in brief
Young Kwon discloses dealings in Adma Biologics, Inc. to SEC (Form 4). The record holds 8 filings, for trades running from 25 October 2021 to 9 February 2026.
The open-market side counts 2 purchases for €176k alongside 1 sale for €986k. Sales outweigh purchases by €809k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 5 share grants.
The latest filing, published on 11 February 2026, reports a share grant in Adma Biologics, Inc. The latest purchase dates back some time: it was published 1,151 days ago, on 24 August 2023. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Young Kwon
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
10,690 shares0Common StockSEC:0001140361-26-004889:0
10,889 shares0Common StockSEC:0001140361-25-005540:0
60,000 shares@ US$18.2679.0% of flowCommon StockSEC:0001140361-24-038770:0
24,040 shares0Common StockSEC:0001140361-24-010239:0
25,000 shares@ US$3.907.2% of flowCommon StockSEC:0001140361-23-041191:0
Canonical exit: 22 Nov 2023 (T+90)
25,815 shares0Common StockSEC:0001140361-23-010768:0
26,586 shares0Common StockSEC:0001140361-22-008677:0
100,000 shares@ US$1.007.4% of flowCommon StockSEC:0001140361-21-035382:0
Canonical exit: 23 Jan 2022 (T+90)
8 of 8 declarations
